Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Cancer is a clonal disorder derived from a single ancestor cell and its progenies that are
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …

Age-related change in human haematopoiesis causes reduced regenerative capacity,
cytopenias, immune dysfunction and increased risk of blood cancer,–, but the reason for …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

Lung cancer in never smokers (LCINS) is a common cause of cancer mortality but its
genomic landscape is poorly characterized. Here high-coverage whole-genome sequencing …

Tumor behavior is intricately dependent on the oncogenic properties of cancer cells and
their multi-cellular interactions. To understand these dependencies within the wider …

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need
of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene …

Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …